Pharmatalkradio

In this talk, first recorded at the 2022 IO360° Summit, Dr Rachel Haurwitz, CEO, Caribou Biosciences, addresses the big picture view of where the cell therapy field is going and how innovative CRISPR-based editing will help with the treatment of hematologic and solid tumors. Key topics include: Approach that requires highly specific and efficient multiplex genome editingWhat are some of the potential stumbling blocks?What are the tools for solving those challenges?Tackling solid tumors as the next frontier for cell therapies Rachel Haurwitz, PhD, President & CEO, Caribou Biosciences Learn more about the IO360° Summit at www.io360summit.com